AYTU BIOPHARMA, INC Contract with Customer, Refund Liability, Current
AYTU BIOPHARMA, INC (AYTU) had Contract with Customer, Refund Liability, Current of $4.87 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes
us-gaap:ContractWithCustomerRefundLiabilityCurrent · last filed 2026-09-22
- 2026-06-30: Contract with Customer, Refund Liability, Current $4.87M.
- 2026-03-31: Contract with Customer, Refund Liability, Current $5.06M.
- 2025-12-31: Contract with Customer, Refund Liability, Current $6.07M.
- 2025-09-30: Contract with Customer, Refund Liability, Current $5.53M.
| Period end | Contract with Customer, Refund Liability, Current |
|---|---|
| 2026-06-30 | $4.87M 10-K · filed 2026-09-22 |
| 2026-03-31 | $5.06M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $6.07M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $5.53M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $6.81M 10-K · filed 2026-09-22 |
| 2025-03-31 | $6.54M 10-Q · filed 2025-05-14 |
| 2024-06-30 | $4.83M 10-K · filed 2025-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |